To study the efficacy of Gum Arabic as an immuno modulator and anti-inflammatory agent among COVID 19 seropositive patients..Half of participants will receive Gum Arabic and the other half will receive placebo
Randomized placebo controlled trial including COVID 19 seropositive patients will be treated with 30 gram per day for 4 weeks, compared to placebo group treated for the same duration in positive COVID 19 patients. Blood samples will be taken first at base line level, after two weeks and after the intervention after satisfying the inclusion and exclusion criteria. The main objective is to assess the effect of Gum Arabic (acacia Senegal) on immune system among COVID-19 patients. The outcome of this project understand SARS-CoV-2 immune response in COVID patients and the effect of Gum Arabic (Acacia Senegal) consumption to counteract progression of the disease
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
110
Oral Digestion of Gum Arabic to be consumed early morning on daily basis for 4weeks
Oral Digestion of Pectin to be consumed early morning on daily basis for 12 weeks
Omdurman Teaching Hospital
Khartoum, Omdurman, Sudan
Jabra Hospital,
Khartoum, Sudan
Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks )
Changes of the level of Tumor Necrosis Factor (TNF), interleukin IL8,IL6,IL10 from the baseline values
Time frame: 4 weeks
Mortality rate
The percentage of deaths among COVID 19 patients received Gum Arabic compared to placebo
Time frame: from the date of assignment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to two months
Determine viral load in each patient
Change of viral load from Baseline
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.